News
More than half of biotech and pharma job seekers have been looking for their next opportunity for six months or longer, and more than a quarter have searched for over a year, according to a BioSpace LinkedIn poll. Job seekers share their frustrations.
FEATURED STORIES
PD-(L)1×VEGF bispecifics have emerged as a closely watched new class in immuno-oncology, with multiple candidates advancing through trials in lung cancer. But the potential of these drugs may be highest in cancers where angiogenesis and immune escape are tightly intertwined.
From Eli Lilly’s David Ricks to Pfizer’s Albert Bourla, the top five highest paid CEOs made a combined $157.8 million in 2025.
Partners Summit Therapeutics and Akeso are expected to steal the show at the American Society of Clinical Oncology’s annual conference with data from their potential Keytruda rival, alongside Revolution Medicine’s groundbreaking pancreatic cancer candidate and other assets that could reshape patient care.
FROM OUR EDITORS
Read our takes on the biggest stories happening in the industry.
FDA veteran Peter Marks will now shape the future of Eli Lilly’s vaccines work after the buys of Curevo, LimmaTech Biologics and Vaccine Company for up to $3.8 billion total.
THE LATEST
It was a busy week for clinical trial announcements. Here’s a look.
Martin Shkreli will not be able to delay paying nearly $25 million he owes from a civil lawsuit that he and his company employed on Daraprim.
Merck announced that its proposed treatment Keytruda for non-small cell lung cancer delivered positive results from its Phase III trial.
With the International Conference on Alzheimer’s and Parkinson’s Diseases still ongoing, there has been increased news about Alzheimer’s. Here’s a look at just a few of the latest stories.
Athenex announced that it is scaling its operations by more than 50%, while Zosano Pharma announced that it is reducing its workforce by around 31%.
California-based Apexigen and two other companies are planning to move to the Nasdaq Stock Exchange following their mergers with SPACs.
BioMarin Pharmaceuticals has published positive results in the New England Journal of Medicine from its Phase III clinical trial of valoctocogene roxaparvovec.
Although there is talk of a fourth shot of the COVID-19 vaccine the data so far suggest the benefits may be modest. Continue reading for details and more COVID-19 news.
A closer look at legal action against executives from the company formerly known as JHL Biotech who recruited scientists from Genentech to steal trade secrets related to several cancer drugs.
Lamassu Bio, Inc. is setting its sights on the unmet needs of the pharmaceutical industry as it announces a new venture to develop therapeutics for cancer.